Cargando…
Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia
OBJECTIVES: Different biomarkers such as C-reactive protein (CRP), serum ferritin and D-dimer are used in prognostic assessment of patients with COVID-19 pneumonia. Presepsin (PSP) is a soluble CD14 subtype that has recently been proposed as a novel biomarker in patients with sepsis. The aim of the...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893933/ https://www.ncbi.nlm.nih.gov/pubmed/35248717 http://dx.doi.org/10.1016/j.ijid.2022.02.054 |
_version_ | 1784662524173484032 |
---|---|
author | Assal, Hebatallah Hany Abdelrahman, Safaa Mohamed Abdelbasset, Maha AlyAlden Abdelaziz, Mai Sabry, Irene Mohamed Shaban, Marwa Moawad |
author_facet | Assal, Hebatallah Hany Abdelrahman, Safaa Mohamed Abdelbasset, Maha AlyAlden Abdelaziz, Mai Sabry, Irene Mohamed Shaban, Marwa Moawad |
author_sort | Assal, Hebatallah Hany |
collection | PubMed |
description | OBJECTIVES: Different biomarkers such as C-reactive protein (CRP), serum ferritin and D-dimer are used in prognostic assessment of patients with COVID-19 pneumonia. Presepsin (PSP) is a soluble CD14 subtype that has recently been proposed as a novel biomarker in patients with sepsis. The aim of the current study was to detect the relation of PSP to the outcome of COVID-19 as well as its relation to other inflammatory biomarkers. METHODS: This multicenter retrospective observational study was conducted in Saudi Arabia and Misr International Hospital, Egypt, from January 2021 to May 2021. Hospitalised patients who had positive throat swab of SARS-CoV-2 and radiological evidence of viral pneumonia (moderate and severe forms) were included in the study. Demographics and clinical features, as well as laboratory parameters, including serum ferritin, CRP, D-dimer and PSP, of enrolled patients were retrospectively collected. Pneumonia severity index (PSI) was used to evaluate the severity of pneumonia. RESULTS: A total of 202 hospitalised patients who were diagnosed with COVID-19 pneumonia and tested positive for SARS-CoV-2 RNA were enrolled in our study. Of 202 hospitalised patients, 67 (33.17%) required intensive care unit (ICU) admission. A total of 176 (87.1%) patients survived and were discharged, whereas 26 (12.9%) patients did not survive. PSP level was found to be significantly elevated in nonsurvivor versus survivor group (median [IQR] 978.5 [755.8–1400] vs 516.5 [343.3–720], P<0.001) as well as in ICU versus non-ICU patients (median [IQR] 800 [631–1200] and 446 [320–626], respectively) (P<0.001). Elevated levels were also found to be associated with increased length of hospital stay. Levels above 775 pg/mL were found to be associated with in-hospital mortality (specificity 80%, sensitivity 73%). CONCLUSION: Elevated PSP levels indicated poor outcomes in hospitalised patients with COVID-19 pneumonia and were associated with in-hospital mortality. |
format | Online Article Text |
id | pubmed-8893933 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88939332022-03-04 Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia Assal, Hebatallah Hany Abdelrahman, Safaa Mohamed Abdelbasset, Maha AlyAlden Abdelaziz, Mai Sabry, Irene Mohamed Shaban, Marwa Moawad Int J Infect Dis Article OBJECTIVES: Different biomarkers such as C-reactive protein (CRP), serum ferritin and D-dimer are used in prognostic assessment of patients with COVID-19 pneumonia. Presepsin (PSP) is a soluble CD14 subtype that has recently been proposed as a novel biomarker in patients with sepsis. The aim of the current study was to detect the relation of PSP to the outcome of COVID-19 as well as its relation to other inflammatory biomarkers. METHODS: This multicenter retrospective observational study was conducted in Saudi Arabia and Misr International Hospital, Egypt, from January 2021 to May 2021. Hospitalised patients who had positive throat swab of SARS-CoV-2 and radiological evidence of viral pneumonia (moderate and severe forms) were included in the study. Demographics and clinical features, as well as laboratory parameters, including serum ferritin, CRP, D-dimer and PSP, of enrolled patients were retrospectively collected. Pneumonia severity index (PSI) was used to evaluate the severity of pneumonia. RESULTS: A total of 202 hospitalised patients who were diagnosed with COVID-19 pneumonia and tested positive for SARS-CoV-2 RNA were enrolled in our study. Of 202 hospitalised patients, 67 (33.17%) required intensive care unit (ICU) admission. A total of 176 (87.1%) patients survived and were discharged, whereas 26 (12.9%) patients did not survive. PSP level was found to be significantly elevated in nonsurvivor versus survivor group (median [IQR] 978.5 [755.8–1400] vs 516.5 [343.3–720], P<0.001) as well as in ICU versus non-ICU patients (median [IQR] 800 [631–1200] and 446 [320–626], respectively) (P<0.001). Elevated levels were also found to be associated with increased length of hospital stay. Levels above 775 pg/mL were found to be associated with in-hospital mortality (specificity 80%, sensitivity 73%). CONCLUSION: Elevated PSP levels indicated poor outcomes in hospitalised patients with COVID-19 pneumonia and were associated with in-hospital mortality. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022-05 2022-03-03 /pmc/articles/PMC8893933/ /pubmed/35248717 http://dx.doi.org/10.1016/j.ijid.2022.02.054 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Assal, Hebatallah Hany Abdelrahman, Safaa Mohamed Abdelbasset, Maha AlyAlden Abdelaziz, Mai Sabry, Irene Mohamed Shaban, Marwa Moawad Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia |
title | Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia |
title_full | Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia |
title_fullStr | Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia |
title_full_unstemmed | Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia |
title_short | Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia |
title_sort | presepsin as a novel biomarker in predicting in‐hospital mortality in patients with covid‐19 pneumonia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893933/ https://www.ncbi.nlm.nih.gov/pubmed/35248717 http://dx.doi.org/10.1016/j.ijid.2022.02.054 |
work_keys_str_mv | AT assalhebatallahhany presepsinasanovelbiomarkerinpredictinginhospitalmortalityinpatientswithcovid19pneumonia AT abdelrahmansafaamohamed presepsinasanovelbiomarkerinpredictinginhospitalmortalityinpatientswithcovid19pneumonia AT abdelbassetmahaalyalden presepsinasanovelbiomarkerinpredictinginhospitalmortalityinpatientswithcovid19pneumonia AT abdelazizmai presepsinasanovelbiomarkerinpredictinginhospitalmortalityinpatientswithcovid19pneumonia AT sabryirenemohamed presepsinasanovelbiomarkerinpredictinginhospitalmortalityinpatientswithcovid19pneumonia AT shabanmarwamoawad presepsinasanovelbiomarkerinpredictinginhospitalmortalityinpatientswithcovid19pneumonia |